POZEN Ends US License Agreement With Sanofi

(RTTNews) - POZEN Inc. (POZN) Monday said it agreed with Sanofi US to terminate the license contract to market investigational products PA8140 and PA32540 in US, with effect from November 29.

All rights to the products reverted back to POZEN as on the effective date, the company said. POZEN said it believes that the clinical profile of the drug will meet or exceed the assumptions and the target population could exceed 20 million patients in the US.

POZEN also said that the products' proposed trade name, Yosprala, was provisionally approved by the US FDA. PA8140 will henceforth be referred to as Yosprala 81/40 and PA32540 as Yosprala 325/40.

The approval for the New Drug Application is pending for Yosprala 81/40 and 325/40, and result is scheduled for December 30.